# US 2025/0188083 A1 · Modulators of Histone Acetyltransferase 1 and Methods of Treatment Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0188083 A1
- Document ID: US20250188083A1
- Status: Published application
- Kind: A1
- Application number: 18/573,193
- Filed: 2022-06-27
- Published: 2025-06-12
- Earliest claimed: 2021-06-25
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Joshua James Gruber; Andrew Lipchik; Michael P. Snyder; Steven R. Schow
- Web page: https://patentgrep.com/patent/US20250188083A1

## CPC

- C07D 475/14: Benz [g] pteridines, e.g. riboflavin
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Small molecules compounds and methods of their synthesis are provided. Small molecules identified can inhibit histone acetyltransferase 1 activity. Formulations and medicaments are also provided that are directed to the treatment of human disorders and conditions, such as, for example, neoplasms, cancers, viral, fungal, and parasitic infections, and aging. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.

## Claims

### Claim 1

A compound of formula
or its salt of a suitable acid,
wherein:
R1 is a functional group selected from H, OH, methyl (CH3), ethyl (C2H5), ethyleny (C2H3), ethynyl (C2H), halogen, alkyl, alkoxy, azide (Ns), ether, NO2, or cyanide (CN);
R2 is a functional group selected from H, OH, methyl (CH3), ethyl (C2H5), ethyleny (C2H3), ethynyl (C2H), halogen, alkyl, alkoxy, azide (Ns), ether, NO2, or cyanide (CN);
R3 is a functional group selected from H, glucose, ribose, an alkyl chain, an alkoxy chain, a ribityl chain, OH, (CH2)nOC═OR1′, (CH2)nNR2′R3′, (CH2)nOH, (CHOH)n-alkyl, (CHOH)n-alkyne, (CHOH)n-aryl, (CH2)nOR1′, C(OC═OR1′)n, where R1′ is an alkyl, aryl and R2′ and R3′ are each independently an alkyl, alkene, alkyne, aryl, (CH2)nOH, CHOH-alkyl, CHOH-alkyne, or CHOH-aryl;
R4 is a functional group selected from H, OH, methyl, (CH3), ethyl (C2H6), halogen, alkyl (including cyclic alkyls), alkoxy, azide (Ns), ether, NO2, cyanide (CN), benzyl, and (CH2)n-benzyl; and
n is an independently selected integer selected from 1, 2, 3, or 4.

### Claim 2 (depends on 1)

The compound of formula of claim 1, wherein R1 is a C1 to C3 alkyl and R2 is a halogen.

### Claim 3 (depends on 1)

The compound of formula of claim 1, wherein R1 is ethyl (C2H6) or methyl (CH3) and R2 is F, Cl, or Br.

### Claim 4 (depends on 1)

The compound of formula of claim 1, wherein R1 is ethyl (C2H6) and R2 is Cl.

### Claim 5 (depends on 1)

The compound of formula of claim 1, wherein R2 is a C1 to C3 alkyl and R1 is a halogen.

### Claim 6 (depends on 1)

The compound of formula of claim 1, wherein R2 is ethyl (C2H6) or methyl (CH3) and R1 is F, Cl, or Br.

### Claim 7 (depends on 1)

The compound of formula of claim 1, wherein R2 is ethyl (C2H6) and R1 is Cl.

### Claim 8 (depends on 1)

The compound of formula of claim 1, wherein R1 and R2 are each independently a C1 to C3 alkyl.

### Claim 9 (depends on 1)

The compound of formula of claim 1, wherein R1 and R2 are each independently ethyl (C2H6) or methyl (CH3).

### Claim 10 (depends on 1)

The compound of formula of claim 1, wherein R1 and R2 are each independently ethyl (C2H6).

### Claim 11 (depends on 1)

The compound of formula of claim 1, wherein R1 and R2 are each independently methyl (CH3).

### Claim 12 (depends on 1)

The compound of formula of claim 1, wherein R1 and R2 are each independently a halogen.

### Claim 13 (depends on 1)

The compound of formula of claim 1, wherein R1 and R2 are each independently F, Cl, or Br.

### Claim 14 (depends on 1)

The compound of formula of claim 1, wherein R1 and R2 are each independently C1.

### Claim 15 (depends on 1)

The compound of formula of claim 1, wherein R3 is ribose, an alkyl chain, an alkoxy chain, or a ribityl chain.

### Claim 16 (depends on 1)

The compound of formula of claim 1, wherein R3 is ribose,

### Claim at position 17

17-70. (canceled)

### Claim 71

A method of treatment of a mammalian disorder or condition comprising: administering a pharmaceutical formulation to a mammalian subject, the pharmaceutical formulation containing a therapeutically effective amount of one or more small molecule compounds having the formula
or an acceptable pharmaceutical salt thereof,
wherein:
R is a functional group selected from H, glucose, ribose, an alkyl chain, an alkoxy chain, a ribityl chain, OH, (CH2)nOC═OR1′, (CH2)nNR2′R3′, (CH2)nOH, (CHOH)n-alkyl, (CHOH)n-alkyne, (CHOH)n-aryl, (CH2)nOR1′, C(OC═OR1′)n, where R1′ is an alkyl, alkene, alkyne, aryl and R2′ and R3′ are each independently an alkyl, alkene, alkyne, aryl, (CH2)nOH, CHOH-alkyl, CHOH-alkyne, or CHOH-aryl; and
n is an independently selected integer selected from 1, 2, 3, or 4.

### Claim 72

(canceled)

### Claim 73 (depends on 71)

The method of claim 71, wherein the mammalian disorder or condition is a neoplasm, and wherein the neoplasm is selected from one or more of the group: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), anal cancer, astrocytomas, basal cell carcinoma, bile duct cancer, bladder cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia (CLL) chronic myelogenous leukemia (CML), chronic myeloproliferative neoplasms, colorectal cancer, endometrial cancer, ependymoma, esophageal cancer, neuroblastoma, Ewing sarcoma, fallopian tube cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, hairy cell leukemia, hepatocellular cancer, Hodgkin lymphoma, hypopharyngeal cancer, Kaposi sarcoma, Kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, Merkel cell cancer, mesothelioma, mouth cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic neuroendocrine tumors, pharyngeal cancer, pituitary tumor, prostate cancer, rectal cancer, renal cell cancer, retinoblastoma, skin cancer, small cell lung cancer, small intestine cancer, squamous neck cancer, T-cell lymphoma, testicular cancer, thymoma, thyroid cancer, uterine cancer, vaginal cancer, and vascular tumors.

### Claim at position 21

74-94. (canceled)

### Claim 95 (depends on 1)

The compound of claim 1, wherein the compound is JG-2016.

### Claim 96 (depends on 71)

The method of claim 71, wherein the one or more small molecule compounds comprises JG-2016.
